Pharmacists should be aware of the rapidly expanding illicit drug market and how they can play a role in reducing harm from popular novel psychoactive substances.
The UK government recognises that cannabis-based medicines could benefit children with epilepsy, but more robust effectiveness and safety data is required before the products can become widely available.
Collective amnesia in the NHS means that major issues affecting patient safety, such as medication errors, are not being adequately addressed, writes David Cousins.
By using Oncotype DX test technology, researchers behind the TAILORx trial have proven that invasive and often harmful chemotherapy needn’t be the only option for women with breast cancer.
Though commonplace in other countries, pharmacogenomic testing is yet to become a mainstay of NHS healthcare. Here, David Wright and Dhiren Bhatt argue how this process could improve the chance of therapeutic success and why pharmacists should be at the heart of its implementation.